Literature DB >> 30447997

Local control, safety, and survival following image-guided percutaneous microwave thermal ablation in primary lung malignancy.

M T Tsakok1, M W Little1, G Hynes2, R S Millington1, P Boardman1, F V Gleeson1, E M Anderson3.   

Abstract

AIM: To determine local control, safety, and survival following percutaneous computed tomography (CT)-guided high-power microwave ablation (MWA) in the treatment of primary lung malignancy at a single institution.
MATERIAL AND METHODS: From July 2010 to June 2016, 52 patients (mean age 76.3 years, range 55-91 years) with 61 unresectable primary lung cancers of mean diameter 23.8 mm (range 26-55 mm) underwent MWA in 55 ablation sessions. Tumours were diagnosed at biopsy, or positron-emission tomography (PET) avidity (mean SUV max = 10.51) and interval growth. Statistical analysis was performed by Kaplan-Meier modelling and Cox and logistic regression.
RESULTS: Local tumour progression (LTP) was diagnosed in six lesions (10%). Median time to local recurrence was 3 months (range 2-14 months). There was a near 12-fold increased odds of local recurrence if the lesion size was >3 cm (95% confidence interval [CI]: 1.84-75.14; p=0.009). The median inpatient stay was 1 day, with no intra-procedural deaths and a 0% 30-day post-ablation mortality rate. Pneumothorax requiring drain was the most serious complication, occurring in 22% (n=12) of patients. Presence of severe emphysema and predicted forced expiratory volume in 1 second (FEV1) of <50% were found to predict future requirement of a drain (odds ratio [OR] 8.17, 95% CI: 1.62-41.37, p=0.01 and OR: 5.14, 95% CI: 1.28-20.68, p=0.02 respectively), when adjusted for age and gender. Tumour size >3 cm had a hazard ratio of 4.37 compared with tumour size ≤3 cm (95% CI: 1.45-13.17, p=0.009) of risk of cancer death at any time, by Cox regression.
CONCLUSION: MWA for primary lung malignancy is a safe and effective treatment for primary lung tumours with outcomes that may be comparable to stereotactic body radiation therapy.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Mesh:

Year:  2018        PMID: 30447997     DOI: 10.1016/j.crad.2018.09.014

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  6 in total

Review 1.  Microwave Ablation in Primary Lung Malignancies.

Authors:  Amgad M Moussa; Etay Ziv; Stephen B Solomon; Juan C Camacho
Journal:  Semin Intervent Radiol       Date:  2019-10-31       Impact factor: 1.513

2.  Bronchoscopically delivered microwave ablation in an in vivo porcine lung model.

Authors:  Jan Sebek; Steve Kramer; Rob Rocha; Kun-Chang Yu; Radoslav Bortel; Warren L Beard; David S Biller; David S Hodgson; Charan K Ganta; Henky Wibowo; John Yee; Renelle Myers; Stephen Lam; Punit Prakash
Journal:  ERJ Open Res       Date:  2020-10-13

3.  Magnetic Hyperthermia Nanoarchitectonics via Iron Oxide Nanoparticles Stabilised by Oleic Acid: Anti-Tumour Efficiency and Safety Evaluation in Animals with Transplanted Carcinoma.

Authors:  Oleg A Kulikov; Mikhail N Zharkov; Valentin P Ageev; Denis E Yakobson; Vasilisa I Shlyapkina; Andrey V Zaborovskiy; Vera I Inchina; Larisa A Balykova; Alexander M Tishin; Gleb B Sukhorukov; Nikolay A Pyataev
Journal:  Int J Mol Sci       Date:  2022-04-11       Impact factor: 6.208

4.  Phase I study of cancer lesion-targeted microwave coagulation therapy for localized prostate cancer: A pilot clinical study protocol.

Authors:  Yasuhiro Yamada; Takumi Shiaishi; Akihisa Ueno; Masatomo Kaneko; Yuta Inoue; Atsuko Fujihara; Fumiya Hongo; Osamu Ukimura
Journal:  Contemp Clin Trials Commun       Date:  2019-10-12

5.  Microwave ablation via a flexible catheter for the treatment of nonsurgical peripheral lung cancer: A pilot study.

Authors:  Fangfang Xie; Junxiang Chen; Yifeng Jiang; Jiayuan Sun; D Kyle Hogarth; Felix J F Herth
Journal:  Thorac Cancer       Date:  2022-02-14       Impact factor: 3.500

6.  Microwave ablation for the management of pulmonary inflammatory myofibroblastic tumor: a case report and literature review.

Authors:  Yizhong Zhang; Guoping Zheng; Xiaopeng Meng; Yuanjing Li; Dan Shi; Jinna Yu
Journal:  Transl Cancer Res       Date:  2021-10       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.